If you’ve spent any time online lately, you’ve probably seen the term “GLP-3” floating around — usually described as the next step after GLP-1 drugs like Ozempic and Wegovy. It sounds official, almost like a sequel. But the actual story is a little more specific and a little different from what the name implies.
Bodies, health conditions, and relationships with food are all different, and none of what follows is meant to suggest there’s one “right” way to look or eat.
What Are GLP-3s Exactly?
“GLP-3” is not an official medical term. There’s no hormone in the human body called GLP-3, and no receptor by that name either. It’s internet shorthand that emerged to describe a new category of “triple-agonist” medications — drugs designed to act on three different hormone receptors at once, rather than just one.
The name is a reference to GLP-1 (glucagon-like peptide-1), the hormone that earlier drugs like semaglutide (Wegovy, Ozempic) were built around. Since the new triple-target drugs go a step further, “GLP-3” caught on as a casual way to describe them — even though, technically, it’s a nickname rather than a diagnosis-code kind of term.
How We Got Here: GLP-1, Then Dual, Then Triple
To understand what’s new, it helps to see the progression:
- GLP-1 drugs (like semaglutide) act on a single hormone pathway. GLP-1 is a hormone your gut naturally releases after eating — it slows how fast your stomach empties, helps regulate blood sugar, and signals fullness to your brain.
- Dual agonists (like tirzepatide, sold as Zepbound or Mounjaro) act on two pathways at once — GLP-1 plus GIP (glucose-dependent insulinotropic polypeptide), another gut hormone involved in blood sugar regulation.
- Triple agonists — the drugs now nicknamed “GLP-3s” — add a third target: the glucagon receptor, which is involved in energy expenditure and how the body uses stored fat. The idea behind combining all three is that each pathway contributes something different — appetite reduction, blood sugar control, and increased energy use — and together they may produce a bigger effect than any single pathway alone.
What Is Retatrutide?
Right now, one drug dominates almost every conversation about GLP-3s: retatrutide, developed by Eli Lilly. It’s the most advanced triple-agonist compound in testing, and most of what’s currently known about this drug class comes from trials of this specific medication.
Where it stands in testing: Phase 2 trial results, published in the New England Journal of Medicine in 2023, showed substantial reductions in body weight among participants over 48 weeks.
More recently, Phase 3 results from a trial called TRANSCEND-T2D-1, focused specifically on people with type 2 diabetes, were published in The Lancet in 2026. That trial found meaningful improvements in blood sugar control alongside weight loss, with the majority of participants on higher doses achieving both better blood sugar levels and at least 10% weight loss over 40 weeks.
Important context: Retatrutide is still investigational. As of now, it is not FDA-approved. Eli Lilly is expected to file for approval later in 2026, with a decision that would likely follow in 2027. Until that process finishes, it isn’t something a doctor can currently prescribe outside of clinical trials.
What the Trial Numbers Actually Mean
You’ll see some striking numbers attached to this drug class — including reports of participants losing more than a quarter of their body weight in trials lasting over a year.
These are average results from controlled clinical trials, not universal outcomes or a promise of what any individual would experience. Trial participants are carefully selected, monitored closely by medical teams, and often started specifically because they had type 2 diabetes or a weight-related health condition their doctor was treating. Individual results vary widely, and these medications, if and when approved, would be prescribed based on a person’s full medical picture, not a headline percentage.
Weight and health are not the same thing, and a lower number on a scale isn’t automatically a marker of a healthier or more worthy body. These drugs are being studied as treatments for specific diagnosed conditions — type 2 diabetes and obesity as classified by a doctor using more than appearance alone — not as a general recommendation for how anyone “should” look.
What Side Effects Have Shown Up So Far
Every source covering this drug class points to the same pattern: gastrointestinal side effects are the most common, similar to what’s seen with GLP-1 and dual-agonist drugs already on the market. In trials, these included nausea and diarrhea, generally described as mild to moderate and improving over time.
Less common side effects that have been raised in reporting on this drug class include pancreatitis, gallstones, and heart arrhythmia. Because retatrutide is still in trials, long-term safety data — what happens over years of use, not months — is still being collected. That’s a normal, expected part of the drug development process, not a red flag specific to this medication, but it does mean the full safety picture isn’t complete yet.
Why This Matters for People Already on GLP-1s
If you’re already using a GLP-1 or dual-agonist medication, it’s reasonable to wonder whether you should be thinking about “upgrading” once a triple agonist becomes available. A few grounded points here:
- “Newer” and “more” don’t automatically mean “better for you specifically.” A medication that produces a bigger average effect in a trial isn’t necessarily the right fit for any given person’s health needs, risk factors, or goals. What’s appropriate depends on someone’s full medical history — something only a doctor working directly with that person can assess.
- Access and cost remain real barriers. Current GLP-1 medications often cost over $1,000 a month without insurance coverage, and coverage itself is inconsistent. There’s no indication a newly approved triple-agonist drug would be more accessible, at least initially — new medications are typically priced at a premium when they first reach the market.
- These aren’t interchangeable, and they’re not something to self-manage. Because retatrutide isn’t approved yet, any use of it outside formal clinical trials would mean sourcing it from unregulated channels — something every reputable source on this topic explicitly warns against, given the incomplete safety data and lack of medical oversight involved.
Why Researchers Are Pursuing a Third Target At All
GLP-1 alone does several things: It slows digestion, helps regulate insulin release, and signals fullness to the brain. Adding GIP, as dual-agonist drugs do, appears to enhance the blood-sugar-related effects and may improve how the body responds to insulin. Adding a third target — the glucagon receptor — introduces something the first two don’t directly address: energy expenditure, meaning how much energy the body burns rather than just how much a person eats.
Researchers describe this as combining “appetite side” effects (feeling full sooner, eating less) with a “metabolic side” effect (the body using more energy). The theory is that combining both mechanisms could produce a bigger, more sustained result than either one alone — which is part of why trial data for retatrutide has generated so much attention in endocrinology circles specifically, not just consumer weight-loss spaces.
Who These Trials Have Actually Studied
It’s easy to read headlines about a new weight-loss drug and picture it as something aimed at the general public. The actual trial populations are narrower than that.
The Phase 3 TRANSCEND-T2D-1 trial, for instance, enrolled 537 adults specifically diagnosed with type 2 diabetes whose blood sugar wasn’t adequately controlled through diet and exercise alone.
Earlier Phase 2 obesity trials similarly enrolled participants who met specific clinical criteria for obesity, evaluated by a doctor.
GLP-1, Dual, and Triple Agonists: What Actually Changes Between Them
Since so much of the conversation compares these categories, here’s what’s actually different, without ranking one as inherently “better”:
Mechanism: GLP-1 drugs act on one receptor. Dual agonists act on two. Triple agonists (GLP-3s) act on three, adding the glucagon receptor to the mix.
Regulatory status: GLP-1 drugs like semaglutide and dual agonists like tirzepatide are FDA-approved and have been prescribed for years. Triple agonists remain investigational, meaning they haven’t cleared the full approval process yet.
Evidence base: GLP-1 and dual-agonist drugs have years of real-world prescribing data behind them, on top of trial data. Triple agonists currently have trial data only — meaning shorter follow-up periods and a much smaller number of total patients studied so far.
Side effect profile: So far, side effects reported for triple agonists look broadly similar in category to existing GLP-1 and dual-agonist drugs — mostly gastrointestinal — though, again, long-term data doesn’t yet exist for the newer class the way it does for the older ones.
None of this makes one category objectively superior to another for a given person. What’s appropriate depends entirely on individual health circumstances, which is a conversation between a patient and their doctor, not something to determine from an online comparison — including this one.
Questions Worth Asking a Doctor, if This Is Relevant to You
If you have a diagnosed condition like type 2 diabetes or obesity and you’re wondering whether any of this — current GLP-1 drugs, dual agonists, or eventually triple agonists — might be relevant to your care, a few questions tend to help structure that conversation:
- What condition, specifically, would this medication be treating for me?
- What are the realistic risks and benefits given my own health history?
- How would we monitor for side effects, and what would count as a reason to stop?
- Are there other treatment approaches that might fit my situation better, and why would this one be preferred?
- If I’m interested in a newer option like a triple agonist once it’s approved, is there a clinical reason to consider switching, or is my current plan already working well for me?
Bringing a doctor into this conversation, rather than researching and deciding alone, is consistently the guidance across every clinical source covering this drug class.
A Note on How This Conversation Gets Talked About Online
Because “GLP-3” started as internet shorthand rather than a term introduced by a health authority, a lot of what circulates about it online blends real trial data with speculation, marketing language, and sometimes outright hype. A few things worth keeping in mind as you read anything else on this topic:
- Percentages get repeated without context. A weight-loss statistic from a 48-week trial in a specific patient population doesn’t necessarily apply to anyone reading about it, and isn’t a target anyone should feel pressure to hit.
- “Next generation” framing can create pressure that isn’t really about health. It’s easy for the conversation around any new medication to slide from “here’s a treatment option for a diagnosed condition” into “here’s what everyone should be striving for.” Those are different conversations, and it’s worth noticing which one a given article, ad, or influencer post is actually having.
- Medical guidance beats trend-following, every time. Every clinical source on this topic — without exception — frames these medications as something to discuss with a doctor who knows a person’s full health history.
If Reading About Weight-Loss Drugs Is Hard for You Right Now
Content about weight-loss medications, including this article, can be difficult to read for a lot of reasons — a history of disordered eating, chronic dieting, medical trauma, or just living in a culture that talks about bodies in a way that rarely feels neutral. None of that reflects anything about you or your worth, and it’s a completely reasonable reaction to a topic that’s genuinely loaded.
If this is a sensitive area for you, it may help to step away from the endless stream of headlines and statistics about these drugs, since that volume of coverage is designed to be attention-grabbing, not to reflect your specific situation or needs.
Why “Not Approved Yet” Is Worth Taking Seriously
Because retatrutide has generated so much attention, some people have looked for ways to access it before it’s approved — through overseas pharmacies, compounding services, or unregulated online sellers. It’s worth being direct about why every clinical source covering this drug class advises against that.
- The safety data isn’t finished. Approval processes exist specifically to establish dosing, identify who shouldn’t take a medication, and catch rare but serious risks that don’t show up until a drug has been used by a much larger and more diverse population than a clinical trial includes. Skipping that process means skipping the safeguards it’s designed to provide.
- Sourcing outside regulated channels adds separate risks. Unregulated versions of any injectable medication carry risks around purity, correct dosing, and contamination that have nothing to do with the drug itself — they’re risks introduced by an unregulated supply chain.
- There’s no medical oversight. Even once a drug is approved, it’s typically prescribed alongside monitoring — bloodwork, follow-up visits, dose adjustments based on how an individual responds. None of that exists when a medication is obtained outside the healthcare system, which removes exactly the safety net that makes prescription medications usable in the first place.
None of this is about judgment toward anyone who’s considered this route — wanting relief from a health condition, or wanting effective treatment sooner, is an understandable impulse. It’s simply worth knowing that “not yet approved” reflects real, unfinished safety work, not just bureaucratic delay.
What to Expect Next
If Eli Lilly files for FDA approval later in 2026 as currently expected, a decision would likely follow sometime in 2027. Between now and then, expect to see more trial results published — including data on other patient populations, longer follow-up periods, and comparisons against existing GLP-1 and dual-agonist drugs. Other pharmaceutical companies are also reportedly working on their own multi-receptor compounds, so retatrutide is likely to have competitors in this category before long, rather than remaining the only option.
This is a medication still in development, not something available for anyone to start using today, and not something that changes what’s true about existing, approved treatment options in the meantime.